Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts
Tóm tắt
Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF). Ruxolitinib was assessed in JUMP, a large (
Từ khóa
Tài liệu tham khảo
Gupta V. Griesshammer M. Martino B. Foltz L. Tavares R. Al‐Ali H.K. Giraldo P. Guglielmelli P. Lomaia E. Bouard C. Perez Ronco J. Tiwari R.&Raanani P.(2017)Predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded‐access JUMP study PF616.
Jakafi (ruxolitinib)(2017)package insert.Incyte Corporation Wilmington Delaware USA.
Jakavi (ruxolitinib)(2016)[summary of product characteristics].Novartis Pharmaceuticals UK Limited Horsham West Sussex UK.
Passamonti F., 2017, Comparing the safety and efficacy of ruxolitinib (RUX) in patients (PTS) with DIPSS low/intermediate‐1–, intermediate‐2–, and high‐risk myelofibrosis (MF) in JUMP, a phase 3B, expanded‐access study, Haematologica, 102, E1333